Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer

被引:0
|
作者
R Shakya
G A Tarulli
L Sheng
N A Lokman
C Ricciardelli
K I Pishas
C I Selinger
M R J Kohonen-Corish
W A Cooper
A G Turner
P M Neilsen
D F Callen
机构
[1] Centre for Personalised Cancer Medicine,
[2] Cancer Therapeutics Laboratory,undefined
[3] School of Medicine,undefined
[4] Faculty of Health Sciences,undefined
[5] The University of Adelaide,undefined
[6] Dame Roma Mitchell Cancer Research Laboratories (DRMCRL),undefined
[7] School of Medicine,undefined
[8] Faculty of Health Sciences,undefined
[9] The University of Adelaide,undefined
[10] Discipline of Obstetrics and Gynaecology,undefined
[11] School of Medicine,undefined
[12] Faculty of Health Sciences,undefined
[13] Robinson Research Institute,undefined
[14] The University of Adelaide,undefined
[15] Adelaide Proteomics Centre,undefined
[16] School of Molecular and Biological Sciences,undefined
[17] The University of Adelaide,undefined
[18] Royal Prince Alfred Hospital,undefined
[19] The Kinghorn Cancer Centre,undefined
[20] Garvan Institute of Medical Research,undefined
[21] St Vincent's Clinical School,undefined
[22] UNSW Australia,undefined
[23] School of Medicine,undefined
[24] University of Western Sydney,undefined
[25] Parramatta,undefined
[26] New South Wales,undefined
[27] Australia,undefined
[28] Tissue Pathology and Diagnostic Oncology,undefined
[29] Royal Prince Alfred Hospital,undefined
[30] Sydney Medical School,undefined
[31] University of Sydney,undefined
[32] Swinburne University of Technology Sarawak Campus,undefined
来源
Oncogene | 2017年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the ‘secretome’) that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial–mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors.
引用
收藏
页码:4469 / 4480
页数:11
相关论文
共 50 条
  • [1] Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
    Shakya, R.
    Tarulli, G. A.
    Sheng, L.
    Lokman, N. A.
    Ricciardelli, C.
    Pishas, K. I.
    Selinger, C. I.
    Kohonen-Corish, M. R. J.
    Cooper, W. A.
    Turner, A. G.
    Neilsen, P. M.
    Callen, D. F.
    ONCOGENE, 2017, 36 (31) : 4469 - 4480
  • [2] EXPRESSION OF MUTANT P53 PROTEINS IN LUNG-CANCER CORRELATES WITH THE CLASS OF P53 GENE MUTATION
    BODNER, SM
    MINNA, JD
    JENSEN, SM
    DAMICO, D
    CARBONE, D
    MITSUDOMI, T
    FEDORKO, J
    BUCHHAGEN, DL
    NAU, MM
    GAZDAR, AF
    LINNOILA, RI
    ONCOGENE, 1992, 7 (04) : 743 - 749
  • [3] DNAJA1 promotes cancer progression by stabilizing mutant p53
    Iwakuma, Tomoo
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Antisense Oligonucleotide Reduction of Mutant Alpha-1 Antitrypsin Protein for the Treatment of Alpha-1 Antitrypsin Liver Disease
    Guo, Shuling
    Freier, Susan M.
    Booten, Sheri L.
    Watt, Andrew
    Peralta, Raechel Q.
    Blomenkamp, Keith S.
    Teckman, Jeffrey
    Monia, Brett P.
    McCaleb, Michael L.
    GASTROENTEROLOGY, 2012, 142 (05) : S919 - S919
  • [5] Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency
    McElvaney, Noel G.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 : S191 - S196
  • [6] Alpha-1 Antitrypsin and Lung Cell Apoptosis
    Serban, Karina A.
    Petrache, Irina
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 : S146 - S149
  • [7] Pontin, a novel interactor of mutant p53 that promotes mutant p53 gain of function
    Zhao, Yuhan
    Yue, Xuetian
    Hu, Wenwei
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (02)
  • [8] Expression of the p53 family in lung cancer
    Uramoto, Hidetaka
    Sugio, Kenji
    Oyama, Tsunehiro
    Nakata, Shoji
    Ono, Kenji
    Nozoe, Tadahiro
    Yasumoto, Kosei
    ANTICANCER RESEARCH, 2006, 26 (3A) : 1785 - 1790
  • [9] The impact of alpha-1 antitrypsin deficiency alleles on lung cancer survival
    Hernandez-Perez, Jose Maria
    Ramos-Izquierdo, Carolina
    Figueira-Goncalves, Juan Marco
    Martinez-Bugallo, Francisco
    Ramallo-Farina, Yolanda
    Perez-Negrin, Lorenzo
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (02) : 1125 - 1130
  • [10] Alpha-1 antitrypsin phenotypes in patients with lung, prostate and breast cancer
    El-Akawi, Z
    Al-Hindawi, FK
    SAUDI MEDICAL JOURNAL, 2004, 25 (02) : 186 - 189